Double anti-B8572-ADC

Double anti-B8572-ADC is an investigational bispecific antibody-drug conjugate (ADC) being developed by Nanolattix for the treatment of various solid tumors. The agent utilizes a bispecific antibody format, designed to simultaneously target two distinct antigens on cancer cells, conjugated to a cytotoxic payload. This dual-targeting approach is intended to enhance tumor selectivity and therapeutic efficacy while potentially overcoming resistance mechanisms associated with single-antigen targeting. Currently in the preclinical stage of development, Double anti-B8572-ADC is being explored for indications including lung cancer, stomach cancer, and breast cancer. Detailed information regarding its specific molecular targets, linker technology, and cytotoxic payload remains proprietary.